Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

VJVirtual | Molecular profiling and risk classification of patients with MPNs and splanchnic vein thromboses

Jean-Jacques Kiladjian • 26 Aug 2020
Myeloproliferative Neoplasms

Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, discusses molecular profiling and risk classification of patients with myeloproliferative neoplasms (MPNs) and splanchnic vein thromboses, a rare complication of disease. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Jean-Jacques Kiladjian

12-month primary endpoint analysis from the Phase III ROP-ET study of ropeginterferon alfa-2b in ET 2:25
12-month primary endpoint analysis from the Phase III ROP-ET study of ropeginterferon alfa-2b in ET
Jean-Jacques Kiladjian • 8 Dec 2025
Preliminary results from trials targeting mutant CALR for the treatment of MPNs 1:16
Preliminary results from trials targeting mutant CALR for the treatment of MPNs
Jean-Jacques Kiladjian • 13 Jun 2025
The disease-modifying potential of CALR-targeted therapies in MPNs 0:55
The disease-modifying potential of CALR-targeted therapies in MPNs
Jean-Jacques Kiladjian • 13 Jun 2025
The management of MPNs in young patients: transitioning from pediatric to adult care 1:57
The management of MPNs in young patients: transitioning from pediatric to adult care
Jean-Jacques Kiladjian • 13 Jun 2025

Related Videos

Patient-reported outcomes in the Phase III VERIFY trial of rusfertide for polycythemia vera 2:04
Patient-reported outcomes in the Phase III VERIFY trial of rusfertide for polycythemia vera
Aniket Bankar • 8 Dec 2025
12-month primary endpoint analysis from the Phase III ROP-ET study of ropeginterferon alfa-2b in ET 2:25
12-month primary endpoint analysis from the Phase III ROP-ET study of ropeginterferon alfa-2b in ET
Jean-Jacques Kiladjian • 8 Dec 2025
Genome editing for treatment of JAK2 V617F-driven myeloproliferative neoplasms 1:39
Genome editing for treatment of JAK2 V617F-driven myeloproliferative neoplasms
Roman Doll • 7 Dec 2025
Using artificial intelligence to accelerate patient eligibility screening in clinical trials 1:52
Using artificial intelligence to accelerate patient eligibility screening in clinical trials
Aaron Gerds • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals